Compare BAND & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | LCTX |
|---|---|---|
| Founded | 2000 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.6M | 391.1M |
| IPO Year | 2017 | 1996 |
| Metric | BAND | LCTX |
|---|---|---|
| Price | $24.19 | $1.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $24.50 | $5.33 |
| AVG Volume (30 Days) | 439.5K | ★ 982.4K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $204,113,000.00 | $14,556,000.00 |
| Revenue This Year | $15.16 | $109.40 |
| Revenue Next Year | $6.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.26 | ★ 53.24 |
| 52 Week Low | $11.94 | $0.43 |
| 52 Week High | $25.69 | $2.09 |
| Indicator | BAND | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 75.42 | 46.22 |
| Support Level | $13.67 | $1.44 |
| Resistance Level | N/A | $1.80 |
| Average True Range (ATR) | 1.47 | 0.08 |
| MACD | 0.46 | 0.00 |
| Stochastic Oscillator | 85.00 | 36.67 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.